Surgical treatments for obesity

Psychiatric Clinics of North America

Volumn 34, Issue 4, 2011, Pages 881-893

  Vetter, Marion L ^a   Dumon, Kristoffel R ^a   Williams, Noel N ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bariatric surgical procedures; Complications; Enteroendocrine factors; Gastric banding; Gut hormones

Indexed keywords

GHRELIN; GLUCAGON LIKE PEPTIDE 1; PEPTIDE YY;

BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; COMORBIDITY; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; GASTRIC BANDING; HEALTH CARE QUALITY; HORMONE ACTION; HORMONE RELEASE; HUMAN; NATURAL ORIFICE TRANSLUMINAL ENDOSCOPIC SURGERY; OBESITY; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; SURGICAL APPROACH; SURGICAL MORTALITY; SURGICAL TECHNIQUE; WEIGHT REDUCTION;

ANASTOMOSIS, ROUX-EN-Y; BARIATRIC SURGERY; BILIOPANCREATIC DIVERSION; ENDOSCOPY, DIGESTIVE SYSTEM; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; OBESITY; PEPTIDE YY; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 81355153881     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2011.08.012     Document Type: Review

References (60)

1. Taylor K. Bariatric surgery fact sheet American Society for Metabolic & Bariatric Surgery web site, Accessed February 23, 2011. http://www.asbs.org/Newsite07/media/asmbs_fs_surgery.pdf.
2. Colquitt J.L., Picot J., Loveman E., et al. Surgery for obesity. Cochrane Database Syst Rev 2009, 2. CD003641.
3. Gastrointestinal surgery for severe obesity. National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 1992, 55:615S-619S. National Institutes of Health.
4. Cummings D.E., Overduin J., Shannon M.H., et al. Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery. Surg Obes Rel Dis 2005, 1:358-368.
5. Buchwald H., Oien D.M. Metabolic/bariatric surgery worldwide 2008. Obes Surg 2009, 19:1605-1611.
6. Schneider B.E., Mun E.C. Surgical management of morbid obesity. Diabetes Care 2005, 28:475-480.
7. de Jong J.R., van Ramshorst B., Gooszen H.G., et al. Weight loss after laparoscopic adjustable gastric banding is not caused by altered gastric emptying. Obes Surg 2009, 19:287-292.
8. Peterli R., Wölnerhanssen B., Peters T., et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 2009, 250:234-241.
9. Karamanakos S.N., Vagenas K., Kalfarentzos F., et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double-blind study. Ann Surg 2008, 247:401-407.
10. Valderas J.P., Irribarra V., Rubio L., et al. Effects of sleeve gastrectomy and medical treatment for obesity on glucagon-like peptide-1 levels and glucose homeostasis in non-diabetic subjects. Obes Surg 2011, 21:902-909.
11. Valderas J.P., Irribarra V., Boza C., et al. Medical and surgical treatments for obesity have opposite effects on peptide YY and appetite: a prospective study controlled for weight loss. J Clin Endocrinol Metab 2010, 95:1069-1075.
12. Braghetto I., Davanzo C., Korn O., et al. Scintigraphic evaluation of gastric emptying in obese patients submitted to sleeve gastrectomy compared to normal subjects. Obes Surg 2009, 19:1515-1521.
13. Melissas J., Koukouraki S., Askoxylakis J., et al. Sleeve gastrectomy: a restrictive procedures?. Obes Surg 2007, 17:57-62.
14. Rubino F. Bariatric surgery: effects on glucose homeostasis. Curr Opin Clin Nutr Metab Care 2006, 9:497-507.
15. Shah M., Simha V., Garg A. Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status. J Clin Endocrinol Metab 2006, 91:4223-4231.
16. Maggard M., Shugarman L.R., Suttorp M., et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005, 142:547-559.
17. Ferchak C.V., Meneghini L.F. Obesity, bariatric surgery, and type 2 diabetes: a systematic review. Diabetes Metab Res Rev 2004, 20:438-445.
18. Buchwald H., Avidor Y., Braunwald E., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004, 292:1724-1737.
19. Buchwald H., Estok R., Fahrback K., et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009, 122:248-256.
20. Angrisani L., Lorenzo M., Borrelli V. Laparoscopic adjustable gastric banding versus Roux-en-Y gastric bypass: 5-year results of a prospective randomized trial. Surg Obes Relat Disord 2007, 3:127-132.
21. Nguyen N.T., Slone J.A., Nguyen X.M., et al. A prospective randomized trial of laparoscopic gastric bypass versus laparoscopic adjustable gastric banding for the treatment of morbid obesity: Outcomes, quality of life, and costs. Ann Surg 2009, 250:631-641.
22. Himpens J., Dobbeleir J., Peeters G. Long-term results of laparoscopic sleeve gastrectomy for obesity. Ann Surg 2010, 252:319-324.
23. Sjöström L., Lindroos A.K., Peltonen M., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004, 351:2683-2693.
24. Sjöström L., Narbro K., Sjöström D., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007, 357:741-752.
25. Adams T.D., Gress R.E., Smith S.C., et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007, 357:753-761.
26. Flum D.R., Belle S.H., King W.C., et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009, 361:445-454. Longitudinal Assessment of Bariatric Surgery (LABS) Consortium.
27. O'Brien P.E., Dixon J.B., Laurie C., et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med 2006, 144:625-633.
28. Dixon J.B., O'Brien P.D., Playfair J., et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008, 299:316-323.
29. 2. Surg Endosc 2009, 23:1569-1573.
30. FDA expands use of banding system for weight loss U.S. Food and Drug Administration, Accessed March 17, 2011. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm245617.htm.
31. Lautz D., Halperin F., Goebel-Fabbri A., et al. The great debate: medicine versus surgery. What is best for the patient with type 2 diabetes?. Diabetes Care 2011, 34:763-770.
32. 2: a report of 2 cases. Surg Obes Relat Dis 2007, 3:195-197.
33. 2. Diabetologia 2009, 52:1027-1030.
34. Edelson P.K., Dumon K.R., Sonnad S.S., et al. Conventional laparoscopic gastric banding: a comparison of 407 cases. Surg Endosc 2010, 25:1402-1408.
35. Coté G.A., Edmundowicz S.A. Emerging technology: endoluminal treatment of obesity. Gastrointest Endosc 2009, 70:991-999.
36. Targarona E.M., Maldonado E.M., Marzol J.A., et al. Natural orifice transluminal endoscopic surgery: the transvaginal route moving forward from cholecystectomy. World J Gastrointest Surg 2010, 2:179-186.
37. Vollmer K., Holst J.J., Baller B., et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose intolerance. Diabetes 2008, 57:678-687.
38. Guidone C., Manco M., Valera-Mora E., et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 2006, 55:2025-2041.
39. Cummings D.E., Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007, 117:13-23.
40. Cummings D.E., Purnell J.O., Fravo R.S., et al. A preprandial rise in plasma ghrelin suggests a role in meal initiation in humans. Diabetes 2001, 50:1714-1719.
41. Cummings D.E., Shannon M.H. Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss?. J Clin Endocrinol Metab 2003, 88:2999-3002.
42. Tschöp M., Weyer C., Tataranni P.A., et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001, 50:707-709.
43. Cummings D.E., Weigle D.S., Frayo R.S., et al. Human plasma ghrelin levels after diet-induced weight loss and gastric bypass surgery. N Engl J Med 2002, 346:1623-1630.
44. Geloneze B., Tambascia M.A., Pilla V.F., et al. Ghrelin: a gut-brain hormone: effect of gastric bypass surgery. Obes Surg 2003, 13:17-22.
45. Fruhbeck G., Diez-Caballero A., Gil M.J., et al. Plasma ghrelin concentrations following bariatric surgery depend on the functional integrity of the fundus. Int J Obesity 2004, 14:606-612.
46. Faraj M., Havel P.J., Phelis S., et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003, 88:1594-1602.
47. Holdstock C., Engstrom B.E., Obrvall M., et al. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003, 88:3177-3183.
48. Nijhuis J., van Dielen F.M., Buurman W.A., et al. Ghrelin, leptin, and insulin levels after restrictive surgery: a 2 year follow-up study. Obes Surg 2004, 14:783-787.
49. Strader A.D., Woods S.C. Gastrointestinal hormones and food intake. Gastroenterology 2005, 128:175-191.
50. Holst J.J. The physiology of glucagon-like peptide-1. Physiol Rev 2007, 1409-1439.
51. Laferrère B., Teixeira J., McGinty J., et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in type 2 diabetes. J Clin Endocrinol Metab 2008, 93:2379-2385.
52. Laferrère B., Tran H., Egger J., et al. The increase in GLP-1 levels and incretin effect after Roux-en-Y gastric bypass surgery (RYGBP) persists up to 1 year in patients with type 2 diabetes mellitus (T2DM). Obesity 2007, 15:7. (Abstr).
53. Laferrère B., Heshka S., Wang K., et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007, 30:1709-1716.
54. Naslund E., Gryback P., Backman L., et al. Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 1998, 43:945-952.
55. Cummings D.E., Overduin J., Shannon M.H., et al. Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery. Surg Obes Rel Dis 2005, 1:358-368.
56. Horowitz M., Collins P.J., Catteron B.E., Harding P.E., Watts J.M., Shearman D.J. Gastric emptying after gastroplasty for morbid obesity. Br J Surg 1984, 71:435-437.
57. Korner J., Bessler M., Inabnet W., et al. Exaggerated glucagons-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007, 3:597-601.
58. Ballantyne G.H. Peptide YY (1-36) and peptide YY (3-36): Part II. Changes after gastrointestinal surgery and bariatric surgery. Obes Surg 2006, 16:795-803.
59. Le Roux C.W., Batterham R.L., Aylwin S.J., et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006, 147:3-8.
60. Le Roux C.W., Welbourn R., Werling M., et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007, 246:780-785.